Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus Inc (NASDAQ: SLP) is a leading provider of modeling software and consulting services for pharmaceutical research and regulatory compliance. This page serves as the definitive source for official company announcements and market-moving developments.
Access real-time updates on earnings reports, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection helps stakeholders track advancements in ADMET prediction tools, PBPK modeling capabilities, and drug development consulting services.
Discover press releases covering software updates, research collaborations, and industry recognitions. Stay informed about initiatives impacting pharmaceutical R&D efficiency and global regulatory submissions. Content is verified through primary sources to ensure accuracy and relevance.
Bookmark this page for streamlined access to Simulations Plus' latest business developments. Combine these updates with our comprehensive company profile for informed analysis of SLP's market position in computational pharmacology solutions.
Simulations Plus (Nasdaq: SLP), a leader in modeling and simulation solutions across various industries, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29, 2024, in Minneapolis. CEO Shawn O'Connor will represent the company, engaging in one-on-one and small group meetings. This event features over 130 public companies, offering institutional clients the opportunity to meet with corporate management. Attendance is by invitation only.
Simulations Plus has launched GastroPlus® X (GPX™), marking a significant upgrade in PBPK/PBBM modeling and simulation software. This new platform offers advanced models, refined algorithms, and integrated machine learning, alongside an intuitive interface and streamlined workflows. GPX is designed to enhance productivity through ease-of-use and faster processing. The development involved extensive user testing and feedback, resulting in a flexible platform that supports diverse research needs. Notably, GPX includes unique features like true polypharmacy simulations and flexible deployment options, including cloud integration. Available for licensing now, GPX aims to expand Simulations Plus's global market reach.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
